Cargando…
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
BACKGROUND: Immunological non-responders (INRs) lacked CD4 increase despite HIV-viremia suppression on HAART and had an increased risk of disease progression. We assessed immune reconstitution profile upon intensification with maraviroc in INRs. METHODS: We designed a multi-centric, randomized, para...
Autores principales: | Rusconi, Stefano, Vitiello, Paola, Adorni, Fulvio, Colella, Elisa, Focà, Emanuele, Capetti, Amedeo, Meraviglia, Paola, Abeli, Clara, Bonora, Stefano, D’Annunzio, Marco, Biagio, Antonio Di, Di Pietro, Massimo, Butini, Luca, Orofino, Giancarlo, Colafigli, Manuela, d’Ettorre, Gabriella, Francisci, Daniela, Parruti, Giustino, Soria, Alessandro, Buonomini, Anna Rita, Tommasi, Chiara, Mosti, Silvia, Bai, Francesca, Di Nardo Stuppino, Silvia, Morosi, Manuela, Montano, Marco, Tau, Pamela, Merlini, Esther, Marchetti, Giulia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828227/ https://www.ncbi.nlm.nih.gov/pubmed/24244635 http://dx.doi.org/10.1371/journal.pone.0080157 |
Ejemplares similares
-
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010) -
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014) -
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019) -
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017) -
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
por: Maria Bottani, Giulia, et al.
Publicado: (2014)